Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (66.7%)
Phase 41 (33.3%)

Trials by Status

completed125%
unknown125%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_3

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT05198960
completed

DOAC in Unusual Site Venous Thrombosis

NCT03778502
recruitingphase_4

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

NCT04700826
unknownphase_3

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

NCT04727437

Clinical Trials (4)

Showing 4 of 4 trials
NCT05198960Phase 3

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting
NCT03778502

DOAC in Unusual Site Venous Thrombosis

Completed
NCT04700826Phase 4

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

Recruiting
NCT04727437Phase 3

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4